

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B34/ER14 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Acknowledges the original grant duration, manifested in the form of either the implementation or budgeted period, of each country disease component and its constituent grants listed in Table 2 of Section IV to GF/B34/ER14 ("Table 2") is shortened according to the operational flexibility granted to the Secretariat pursuant to GF/B31/DPO9.
4. Approves the reinvestment of within-allocation efficiencies for the Congo (Democratic Republic) malaria grant and its resultant total program budget, as listed in Table 2;
5. Approves the additional incremental funding and implementation period recommended for Mozambique malaria disease component and its constituent grants, as listed in Table 2, based on the available funding that the Finance and Operational Performance Committee (the "FOPC") validated pursuant to GF/FOPC17/DPO2;
6. Affirms the (additional) incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
7. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

Table 1: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation

| N | Country | Disease Component | Proposed Principal Recipient (Grant Name) | Grant End Date | Currency | Total Program Budget | Sources | | Recommended Total Incremental Funding | Incentive Funding included in Total Incremental Funding | Unfunded Quality Demand | Domestic Commitment |
|---|---------|-------------------|-------------------------------------------|------------------|----------|----------------------|------------------|---------------------------------|---------------------------------------|---------------------------------------------------------|-------------------------|---------------------|
| | | | | | | | Existing Funding | Recommended Incremental Funding | | | | |
| 1 | Liberia | TB/HIV | LBR-C-MOH | 31 December 2017 | US\$ | 37,612,921 | 28,028,831 | 0 | 9,584,090 | n/a | 0 | TB: 0.69 million |
| | | | LBR-H-PSI | 31 December 2017 | US\$ | | 0 | 9,584,090 | | | | HIV: 12.67 million |

Table 2: Secretariat's Recommendation on Shortened Grants

| N | Applicant | Disease Component | Grant Name | Currency | Period of Extension (Months) | Previously Approved Grant Budget | Revised Budget for Board Approval | Original Existing Funding | Additional Existing Funding | Incremental Funding Already Approved | Additional Incremental Funding for Board Approval | Total Additional Incremental Funding for Board Approval | Revised Unfunded Quality Demand |
|---|-----------------------------|-------------------|------------|----------|------------------------------|----------------------------------|-----------------------------------|---------------------------|-----------------------------|--------------------------------------|---------------------------------------------------|---------------------------------------------------------|---------------------------------|
| 1 | Congo (Democratic Republic) | Malaria | COD-M-PSI | US\$ | N/A ¹ | 119,790,157 | 174,052,981 ² | 11,471,707 | 23,885,446 | 108,318,450 | 0 | 0 | 0 |
| 2 | Mozambique | Malaria | MOZ-M-MOH | US\$ | 12 | 84,172,540 | 124,427,280 ³ | 41,066,178 | 0 | 43,106,362 | 43,546,381 | 61,425,363 | 21,389,359 |
| | | | MOZ-M-WV | | 9 | 23,187,703 | 44,881,096 ⁴ | 12,069,839 | 0 | 11,117,864 | 17,878,982 | | |

¹ The original budgeted period is 2 years (1 January 2015 to 31 December 2016) while the implementation period previously approved by the Board is 3 years (until 31 December 2017). Hence, no time extension is requested.

² The revised budget reflects the original approved budget amount of US\$119,790,157, the revised signed budget amount previously notified to the Board of US\$134,224,102 (GF/B34/ER12), the proposed transfer of anticipated savings from COD-M-SANRU of US\$15,943,433 and the reinvestment of cash balances of US\$23,885,446 from closed Round 10 Single Stream of Funding malaria grants (ZAR-M-PSI, ZAR-M-SANRU, ZAR-M-MOH) recommended by the GAC for Board approval.

³ The revised budget reflects the original approved budget amount of US\$84,172,540, the revised signed budget amount of US\$80,880,899 which was reduced as a result of planned disbursements at the time of grant signing, and the additional incremental funding of US\$43,546,381 recommended by the GAC for Board approval.

⁴ The revised budget reflects the original approved budget amount of US\$23,187,703, the revised signed budget amount previously notified to the Board of US\$27,002,115 (GF/B34/ER12), and the additional incremental funding of US\$17,878,982 recommended by the GAC for Board approval.